OptiNose, Inc. (OPTN) News
Filter OPTN News Items
OPTN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPTN News Highlights
- OPTN's 30 day story count now stands at 6.
- Over the past 13 days, the trend for OPTN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about OPTN are DRUG, EAR and SNDA.
Latest OPTN News From Around the Web
Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
US$4.17: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest ResultsShareholders might have noticed that OptiNose, Inc. ( NASDAQ:OPTN ) filed its quarterly result this time last week. The... |
Q1 2023 OptiNose Inc Earnings CallQ1 2023 OptiNose Inc Earnings Call |
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue EstimatesOptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Optinose Reports First Quarter 2023 Financial Results and Operational UpdatesStrong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy spe |
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCEThe application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused |
Optinose Announces Reporting Date for First Quarter 2023 Financial ResultsConference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern TimeYARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before market open on Thursday, May 11, 2023. Company to Host Conference CallMembers of the Company’s leadership team will host a confe |
OptiNose, Inc.'s (NASDAQ:OPTN) Business Is Trailing The Industry But Its Shares Aren'tWith a median price-to-sales (or "P/S") ratio of close to 3.1x in the Pharmaceuticals industry in the United States... |
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 54,000 shares of its common stock to three new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incen |
Optinose to Present at the Needham Virtual Healthcare ConferenceYARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will |
OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call TranscriptOptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. . Please be advised that today’s […] |